
Please fill out this
form carefully:
- Fields marked with (*) are required.
- Characters other than English
letters, numbers or punctuation cannot be accepted by this
website.
POLICY STATEMENT
The International Academy of Cardiology requires that
audiences at the Academy's educational programs be informed of a
presenter's (moderators, speakers, faculty, authors and
contributors) academic and professional affiliations, as well as
other commercial relationships relevant to the content of the
material that is presented. The policy allows the
listener/attendee to be fully informed in evaluating the
information being presented. The situations may include, but are
not limited to 1) stock options or bond holdings in a for-profit
corporation or self-directed pension plan, 2) research grants,
3) employment (full or part time), 4) ownership or partnership,
5) consulting fees or other remuneration received by the
presenter or his/her immediate family, including support that
may be provided to attend the educational meeting, 6)
nonremunerative positions of influence such as officer, board
member, trustee, or public spokesperson. The disclosure will be
shown as an indication (by an *) for those presenters who have
stated that a relationship(s) exists relevant to the topic(s)
being discussed. Indicate any author(s) who has a possible
conflict of interest (see policy statement) by an asterisk (*)
next to that author(s) name in the heading of the abstract.
|
|
PRESENTING AUTHOR'S PERSONAL DETAILS: |
| Family
name / Surname:(*) |
|
| First name
and middle initial(s):(*) |
|
| Title: |
|
| Mailing
Address |
|
Position:
complete this field only if
it is part of your mailing address |
|
Institution/Organization:
complete this field only if
it is part of your mailing address
|
|
Department:
complete this field only if
it is part of your mailing address
|
|
| Address:(*) |
|
| |
|
| City:(*) |
|
| State: |
|
| Country:(*) |
|
| Postal
code:(*) |
|
Work Phone (office
hours):
(*)
Country code/city code/number |
|
Home Phone
Country code/city code/number |
|
Fax:
Country code/city
code/number |
|
| E-mail
address:(*) |
|
| Additional/alternative email
address |
|
|
PREFERRED PRESENTATION TYPE (*) |
| |
|
Oral presentation |
|
Poster presentation |
|
Oral / Poster presentation |
| |
| To be completed by
Faculty Members ONLY: |
|
This is the abstract of my invited presentation
|
| |
|
AUTHOR AFFILIATION
(*) |
Please list
ALL author(s) institution affiliations, in order to refer to
them by their number later (see below).
The authors must also include the following:
Institution, City, State, Country (i.e.,
Columbia University, New York, NY, USA)
|
| |
| AUTHORS
(*) |
|
| |
|
Please list all authors in the order
they should appear in the publication.
In the affiliation field please
enter the number corresponding to the city and country listed
above (e.g.: 1).
|
|
|
|
ABSTRACT CATEGORY(*) |
| Select one category,
under which your abstract will be reviewed: |
1. Molecular cardiology, Basic research
2. Vascular biology, Basic research
3. Pharmacologic modulation of vascular-endothelial function
4. Genetic determinants of coronary heart
disease/cardiomyopathies
5. Gene transfer and therapy
6. Biochemical markers of acute ischemia
7. Contrast echocardiography
8. Pharmacologic stress testing - Echocardiography
9. Echocardiography: TEE and 3-D
10. Nuclear Cardiology
11. PET/MRI/CT
12. Other diagnostic methods: Percutaneous coronary
angioscopy / intravascular ultrasound imaging /intracoronary
flow, doppler measurements
13. The plaque and acute coronary syndromes
14. Myocardial stunning, Hibernation and preconditioning
15. Acute myocardial infarction: thrombolysis and
reperfusion
16. Angioplasty therapy for acute MI
17. Stents: new devices/optimal application/multiple stents
18. Antithrombotic and antiplatelet adjunctive therapy for
PTCA
19. Blockade of tissue proliferation after coronary
interventions
20. Restenosis - use of ionizing radiation
21. Nitrates, beta blockers, calcium entry blockers and ACE
inhibition drugs for ischemic heart disease
22. Left ventricular remodeling after MI
23. Secondary prevention, prognosis, risk stratification,
cardiac rehab
24. Modification of lipoproteins and coronary disease
25. Hypertension, basic and clinical
26. Diabetes mellitus, obesity, insulin and atherosclerosis
27. Primary prevention of coronary artery disease in the
healthy adult and children
28. Hormone therapy in postmenopausal women
29. Natriuretic peptides, endothelin: role in heart failure
30. Neurohumoral, immunologic and cytokine aspects of heart
failure
31. Nitric oxide and nitric oxide synthase in heart failure
32. Myocyte and receptor abnormalities in heart failure
33. Dilated cardiomyopathy: various etiologies
34. Left ventricular hypertrophy and hypertrophic
cardiomyopathy
35. Role of the pericardium - basic and clinical
36. Pulmonary circulation aspects, pulmonary hypertension
37. Predictors and markers of heart failure outcome
38. Exercise physiology in heart failure
39. Renal aspects - diuretics
40. Digoxin and other new inotropic agents in heart failure
41. ACE inhibitors and Angiotensin-ll receptor blockers
42. Organic nitrates-their role in heart failure management
43. Beta-blockers and beta-adrenergic receptors in heart
failure
44. Calcium channel blockers and promoters in heart failure
45. Arrhythmias and antiarrhythmic drug therapy - basic and
clinical
46. Sudden death
47. Electrophysiologic techniques of mapping and
radiofrequency ablation
48. Internal defibrillation/implantable antiarrhythmic
devices/pacing
49. Pediatric cardiology and cardiac surgery/congenital
heart disease
50. Angioplasty or surgery for multivessel coronary artery
disease
51. New approaches to surgical revascularization: minimally
invasive surgery, TMLR
52. Valvular heart disease/Heart valve surgery-adult
53. Mechanical support left ventricular assist devices
54. Surgery for LV dysfunction
55. Cardiac transplantation
56. Practice guidelines, cost containment
57. Computers in cardiology
58. Miscellaneous
|
|
Please select: |
| |
| |
|
ABSTRACT TITLE (*)
Please enter the title in UPPERCASE: |
|
|
| |
| |
|
Abstract Body: (*) |
Please note:
- Symbols, Sub and Super
Script cannot be used in
this form. Symbols may be written in full (e.g. alpha,
beta).
- Characters other than
English letters, numbers or punctuation
cannot be accepted by this website.
- The abstract text should
not exceed 250 words.
|
|
| |
PLEASE NOTE: After
submitting abstract, you will see an on-screen message "...your
registration has been received" and a reference number will be
given to you. This indicates your abstract has entered the
system for processing.
|
Please press the
"Submit" button ONCE only.
|
|